JP2017516820A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516820A5 JP2017516820A5 JP2016570876A JP2016570876A JP2017516820A5 JP 2017516820 A5 JP2017516820 A5 JP 2017516820A5 JP 2016570876 A JP2016570876 A JP 2016570876A JP 2016570876 A JP2016570876 A JP 2016570876A JP 2017516820 A5 JP2017516820 A5 JP 2017516820A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- pufa
- polyunsaturated fatty
- fatty acids
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 19
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 19
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims 7
- 229930195729 fatty acid Natural products 0.000 claims 7
- 239000000194 fatty acid Substances 0.000 claims 7
- 150000004665 fatty acids Chemical class 0.000 claims 7
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 6
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 6
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 5
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 3
- 235000021283 resveratrol Nutrition 0.000 claims 3
- 229940016667 resveratrol Drugs 0.000 claims 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 2
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims 2
- 125000005907 alkyl ester group Chemical group 0.000 claims 2
- ITNKVODZACVXDS-YNUSHXQLSA-N ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate Chemical compound CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC ITNKVODZACVXDS-YNUSHXQLSA-N 0.000 claims 2
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- 229940067606 lecithin Drugs 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 239000001828 Gelatine Substances 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000005515 coenzyme Substances 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000419 plant extract Substances 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14001941.5A EP2952209B1 (en) | 2014-06-04 | 2014-06-04 | Homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration |
| EP14001941.5 | 2014-06-04 | ||
| PCT/EP2015/056524 WO2015185238A1 (en) | 2014-06-04 | 2015-03-26 | Homogeneous formulation comprising omega-3 polyunsatured fatty acid and resveratrol for oral administration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516820A JP2017516820A (ja) | 2017-06-22 |
| JP2017516820A5 true JP2017516820A5 (enExample) | 2018-07-05 |
| JP6552526B2 JP6552526B2 (ja) | 2019-07-31 |
Family
ID=50884651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570876A Expired - Fee Related JP6552526B2 (ja) | 2014-06-04 | 2015-03-26 | ω−３多価不飽和脂肪酸及びレスベラトロールを含む経口投与用均質処方物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10300035B2 (enExample) |
| EP (1) | EP2952209B1 (enExample) |
| JP (1) | JP6552526B2 (enExample) |
| CN (1) | CN106456783B (enExample) |
| AU (1) | AU2015271277A1 (enExample) |
| CA (1) | CA2943000A1 (enExample) |
| EA (1) | EA032717B1 (enExample) |
| ES (1) | ES2666836T3 (enExample) |
| MX (1) | MX361765B (enExample) |
| PL (1) | PL2952209T3 (enExample) |
| PT (1) | PT2952209T (enExample) |
| UA (1) | UA118289C2 (enExample) |
| WO (1) | WO2015185238A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250006294A (ko) * | 2022-05-06 | 2025-01-10 | 선포레스트 (베이징) 바이오팜 엘티디 | 세포막 막횡단 수송과 유동성을 조절하는 탄소사슬 물질, 제조 및 응용 |
| CN114569726B (zh) * | 2022-05-06 | 2022-10-28 | 太阳雨林(北京)生物医药有限公司 | 预防、阻止或治疗微生物感染的复合物及制备方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1306722B1 (it) * | 1999-10-08 | 2001-10-02 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di |
| ITRM20020562A1 (it) | 2002-11-06 | 2004-05-07 | Sigma Tau Ind Farmaceuti | Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza. |
| DK1863570T3 (da) * | 2005-03-11 | 2011-06-20 | Recon Oil Ind Private Ltd | Synergistisk varmestabilt oliemedium med eicosapentaensyre (EPA) og decosahexaensyre (DHA) |
| DE202008003509U1 (de) * | 2008-03-12 | 2009-10-15 | Langhoff, Gertrud | Pharmazeutische Zusammensetzung zur Prophylaxe und Behandlung der Arteriosklerose, sowie zur Schmerzbekämpfung und zur Entzündungshemmung |
| KR101100078B1 (ko) * | 2008-03-27 | 2011-12-29 | 홉킨스바이오연구센터(주) | 관절염 치료를 위한 약제학적 조성물 |
| CN102665698A (zh) | 2009-12-23 | 2012-09-12 | 迪菲安特制药有限责任公司 | 可用于治疗心血管疾病的联合组合物 |
| WO2011120530A1 (en) | 2010-03-31 | 2011-10-06 | Lifecycle Phama A/S | Porous tablets as carriers for liquid formulations |
| WO2011162802A1 (en) * | 2010-06-21 | 2011-12-29 | Virun, Inc. | Compositions containing non-polar compounds |
| IT1400695B1 (it) | 2010-06-21 | 2013-06-28 | Labomar S R L | Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle. |
| CN102228089B (zh) * | 2011-06-22 | 2013-02-20 | 刘升胜 | 一种天然复合食用植物健脑营养饮料 |
| KR101418980B1 (ko) * | 2012-04-24 | 2014-07-11 | (주)바이오제닉스 | 난용성 물질을 가용화 하는 다중 라멜라 액정의 제조방법 |
| EP2664329A1 (de) * | 2012-05-15 | 2013-11-20 | F. Holzer GmbH | Ophthalmologisches Vehikelsystem |
| WO2014095628A1 (en) * | 2012-12-17 | 2014-06-26 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa) |
-
2014
- 2014-06-04 EP EP14001941.5A patent/EP2952209B1/en active Active
- 2014-06-04 PT PT140019415T patent/PT2952209T/pt unknown
- 2014-06-04 ES ES14001941.5T patent/ES2666836T3/es active Active
- 2014-06-04 PL PL14001941T patent/PL2952209T3/pl unknown
-
2015
- 2015-03-26 CA CA2943000A patent/CA2943000A1/en not_active Abandoned
- 2015-03-26 JP JP2016570876A patent/JP6552526B2/ja not_active Expired - Fee Related
- 2015-03-26 CN CN201580029857.9A patent/CN106456783B/zh not_active Expired - Fee Related
- 2015-03-26 EA EA201692398A patent/EA032717B1/ru not_active IP Right Cessation
- 2015-03-26 UA UAA201613087A patent/UA118289C2/uk unknown
- 2015-03-26 WO PCT/EP2015/056524 patent/WO2015185238A1/en not_active Ceased
- 2015-03-26 US US15/316,151 patent/US10300035B2/en active Active
- 2015-03-26 AU AU2015271277A patent/AU2015271277A1/en not_active Abandoned
- 2015-03-26 MX MX2016013190A patent/MX361765B/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8563609B2 (en) | Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline | |
| ES2826201T3 (es) | Cápsulas entéricas blandas que comprenden ácidos grasos poliinsaturados | |
| CN104187627B (zh) | 一种降血脂组合物及其在制备具有降血脂功能的保健食品中的应用 | |
| JP2012502090A5 (enExample) | ||
| WO2008147562A3 (en) | Dietary formulations and methods for treatment of inflammation and other disorders | |
| WO2005089744A3 (en) | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma | |
| JP2022542513A (ja) | ω－３脂肪酸塩とボスウェリア種由来のガム樹脂の抽出物とを含む調製物 | |
| JP2015514083A5 (enExample) | ||
| JP2014512351A5 (enExample) | ||
| HRP20161272T4 (hr) | Učinci metaboličkog utiskivanja specifično dizajnirane lipidne komponente | |
| KR20240060826A (ko) | 유로리틴 화합물을 포함하는 조성물 | |
| HRP20160939T1 (hr) | Pripravci za liječenje neuroloških poremećaja | |
| JP2016501248A5 (enExample) | ||
| MX2020014051A (es) | Emulsion lipidica para administracion parenteral. | |
| JP2020121972A (ja) | Ｎａｆｌｄ治療用組成物 | |
| HRP20250125T1 (hr) | Postupci i pripravci povezani s emulzijama koje sadrže riblje ulje i/ili omega-3 masne kiseline | |
| JP2017516820A5 (enExample) | ||
| JP2015510760A5 (enExample) | ||
| JP2012508791A5 (enExample) | ||
| CA2943000A1 (en) | Homogeneous formulation comprising omega-3 polyunsaturated fatty acid and resveratrol for oral administration | |
| WO2014095628A1 (en) | Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa) | |
| JP2017522278A5 (enExample) | ||
| WO2007064010A1 (ja) | アルツハイマー型認知症予防・治療剤 | |
| Dias et al. | Kinetics of omega-3 polyunsaturated fatty acids when co-administered with saturated or omega-6 fats | |
| WO2011128626A1 (en) | Essential fatty acid gelled composition |